262 related articles for article (PubMed ID: 9689330)
1. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
Arai Y; Kubota T; Nakagawa T; Kabuto M; Sato K; Kobayashi H
Acta Neurochir (Wien); 1998; 140(4):377-85; discussion 385-6. PubMed ID: 9689330
[TBL] [Abstract][Full Text] [Related]
2. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Landau BJ; Kwaan HC; Verrusio EN; Brem SS
Cancer Res; 1994 Feb; 54(4):1105-8. PubMed ID: 8313368
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Casslén B; Bossmar T; Lecander I; Astedt B
Eur J Cancer; 1994; 30A(9):1302-9. PubMed ID: 7999418
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical demonstration of the plasminogen activator system in human gingival tissues and gingival fibroblasts.
Xiao Y; Bunn CL; Bartold PM
J Periodontal Res; 1998 Jan; 33(1):17-26. PubMed ID: 9524317
[TBL] [Abstract][Full Text] [Related]
5. Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
Grimsley PG; Normyle JF; Brandt RA; Joulianos G; Chesterman CN; Hogg PJ; Owensby DA
Thromb Res; 1995 Aug; 79(4):353-61. PubMed ID: 7482438
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
[TBL] [Abstract][Full Text] [Related]
8. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator in acute myeloid leukaemic marrows: u-PA in contrast to t-PA in normal marrow.
McWilliam N; Robbie L; Booth N; Bennett B
Br J Haematol; 1998 Jun; 101(4):626-31. PubMed ID: 9674732
[TBL] [Abstract][Full Text] [Related]
10. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Ronday HK; Smits HH; Van Muijen GN; Pruszczynski MS; Dolhain RJ; Van Langelaan EJ; Breedveld FC; Verheijen JH
Br J Rheumatol; 1996 May; 35(5):416-23. PubMed ID: 8646430
[TBL] [Abstract][Full Text] [Related]
11. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
12. Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Kinder DH; Berger MS; Mueller BA; Silber JR
Oncol Res; 1993; 5(10-11):409-14. PubMed ID: 8054701
[TBL] [Abstract][Full Text] [Related]
13. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
14. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
15. Expression profiles of fibrinolytic components in nasal mucosa.
Sejima T; Madoiwa S; Mimuro J; Sugo T; Ishida T; Ichimura K; Sakata Y
Histochem Cell Biol; 2004 Jul; 122(1):61-73. PubMed ID: 15197554
[TBL] [Abstract][Full Text] [Related]
16. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Plas E; Carroll VA; Jilch R; Mihaly J; Vesely M; Ulrich W; Pflüger H; Binder BR
Int J Cancer; 1998 Oct; 78(3):320-5. PubMed ID: 9766566
[TBL] [Abstract][Full Text] [Related]
17. Variations of components of the plasminogen activation system with the cell cycle in benign prostate tissue and prostate cancer.
Plas E; Carroll VA; Jilch R; Simak R; Mihaly J; Melchior S; Thüroff JW; Binder BR; Pflüger H
Cytometry; 2001 Jun; 46(3):184-9. PubMed ID: 11449410
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
19. The plasminogen-activation system in ovarian tumors.
Pujade-Lauraine E; Lu H; Mirshahi S; Soria J; Soria C; Bernadou A; Kruithof EK; Lijnen HR; Burtin P
Int J Cancer; 1993 Aug; 55(1):27-31. PubMed ID: 8344749
[TBL] [Abstract][Full Text] [Related]
20. [Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients].
Xiao W; Tong WL; Ma DD
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Nov; 29(11):723-6. PubMed ID: 17327049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]